Press Releases May 1, 2026 08:00 AM

Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET

Vaxart schedules Q1 2026 earnings release and stockholder virtual fireside chat

By Nina Shah VXRT
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
VXRT

Vaxart, a clinical-stage biotechnology company developing oral recombinant vaccines, announced it will report its Q1 2026 financial results on May 7, 2026, followed by a virtual stockholder fireside chat hosted by senior management on May 8. The company focuses on pill vaccines that do not require refrigeration and aims to develop vaccines for coronavirus, norovirus, influenza, and HPV. Investors can submit questions in advance and access a replay of the event on Vaxart's website.

Key Points

  • Vaxart to report Q1 2026 financial results after market close on May 7, 2026.
  • Company will hold a virtual fireside chat on May 8, 2026 to address stockholder questions.
  • Vaxart specializes in oral recombinant vaccines delivered via pill format, targeting major infectious diseases and immune-oncology indications.
  • The company's proprietary delivery platform offers logistical advantages by eliminating refrigeration needs and needle-stick injuries.

Company to report first quarter 2026 financial results on May 7

SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced that members of the Company’s senior management team will participate in a virtual fireside chat on Friday, May 8, 2026 at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular series to answer frequently asked questions from its stockholders. The Company plans to report financial results for the first quarter ended March 31, 2026, after the market close on Thursday, May 7, 2026.

The live fireside chat can be accessed by clicking here or on the Company’s website at www.vaxart.com.

Investors may submit written questions in advance of the conference call to [email protected] or through the webcast portal.

A replay of the fireside chat webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact
Vaxart Media and Investor Relations:
FINN Partners
[email protected]


Risks

  • Financial results could reflect uncertainties typical of clinical-stage biotech companies, impacting investor sentiment.
  • Success of development programs depends on clinical trial outcomes and regulatory approvals, introducing significant risk.
  • Market adoption and competition in the vaccine sector could affect Vaxart's commercial prospects.

More from Press Releases

TWFG Insurance Acquires APIA Inc., Expanding Specialty MGA Capabilities and Supporting Long-Term Growth May 4, 2026 Pennant Announces First Quarter 2026 Earnings Release and Call May 4, 2026 Magna Announces 2026 Annual Meeting Results May 4, 2026 Sprott Physical Copper Trust Updates Its “At-The-Market” Equity Program in Connection with NYSE Arca Listing May 4, 2026 Grupo Aeroportuario del Pacifico Reports on Impact Arising from the Cessation of Operations of Spirit Airlines May 4, 2026